Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy

Sungjae Kim, Sabine Allam, Yoshinobu Konishi et al. Nov 03, 2025 pp. 582-582 10.1182/blood-2025-582

Abstract INTRODUCTION Recent advances in mass spectrometry (MS) have enabled the detection of low-level monoclonal immunoglobulins previousl...

Barriers to receiving CAR T-cell treatment among patients with non-Hodgkin lymphoma who were deemed eligible for CAR T-cell therapy

Andrew Park, Selin Cooper, Sheila Mpima et al. Nov 03, 2025 pp. 2721-2721 10.1182/blood-2025-2721

Abstract Background: Advances in non-Hodgkin lymphoma (NHL) treatment options, such as chimeric antigen receptor T-cell therapies (CAR T) an...

Exploring the multi-target pharmacology of ginseng against Acute Myeloid Leukemia by integrating single-cell sequencing, molecular docking, and network pharmacology

Yan Zhang, Bobin Su, Changqing Jiao et al. Nov 03, 2025 pp. 6773-6773 10.1182/blood-2025-6773

Abstract Background: Acute myeloid leukemia (AML) is a heterogeneous disease. It is characterized by the rapid clonal expansion of abnormall...

Discovery of the transcription factor ZNF683/hobit as a central regulator of pathogenic T cell proliferation in acute gvhd

Alexandre Albanese, Edward Chen, Yvonne Suessmuth et al. Nov 03, 2025 pp. 275-275 10.1182/blood-2025-275

Abstract Background: Severe acute GVHD (aGVHD) remains a major cause of mortality after transplant, especially with CNI/MTX prophylaxis. How...

Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel)

Amer Beitinjaneh, Supriya Gupta, Fateeha Furqan et al. Nov 03, 2025 pp. 3606-3606 10.1182/blood-2025-3606

Abstract Introduction: Brexu-cel is a CAR T-cell therapy approved in the US for adults with R/R MCL and has demonstrated durable responses an...

A mixed methods evaluation of American society of Hematology's (ASH) clinical guidelines

Marshall Cheney, Austin Smith, Toby Clampitt et al. Nov 03, 2025 pp. 2873-2873 10.1182/blood-2025-2873

Abstract Introduction: Clinical guidelines are evidence-based recommendations for diagnosing and treating a medical condition. Guideline rec...

Social determinants of health and long-term survival in chronic lymphocytic leukemia/small lymphocytic lymphoma: A population-based analysis of 118,667 patients

Xiaoyi Zhang, R. Alejandro Sica, Na Xiao et al. Nov 03, 2025 pp. 2780-2780 10.1182/blood-2025-2780

Abstract Background: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) exhibits heterogeneous outcomes influenced by biologi...

Real-world one-month mortality and bleeding outcomes with caplacizumab in thrombotic thrombocytopenic purpura: A propensity-matched cohort study

Kanishka Uttam Chandani, Usman Ilyas, Ritu C. Tated et al. Nov 03, 2025 pp. 4892-4892 10.1182/blood-2025-4892

Abstract Background Thrombotic Thrombocytopenic Purpura (TTP) is a rare, typically acquired disorder due to an immune-mediated deficiency of...

Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis

Xi Yang, Henry Dumke, Joseph Schroers-Martin et al. Nov 03, 2025 pp. 783-783 10.1182/blood-2025-783

Abstract Introduction: Primary mediastinal B-Cell lymphoma (PMBCL) is a rare form of large B-Cell lymphoma (LBCL) with around 90% of patient...

Effects of golidocitinib and gecacitinib in mouse models of primary and secondary hemophagocytic lymphohistiocytosis

Yijun Wu, Xu Sun, Kai Kang et al. Nov 03, 2025 pp. 1215-1215 10.1182/blood-2025-1215

Abstract Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening cytokine storm syndrome caused by immune hyperactivati...

Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma

Ilaria Vigliotta, Alessia Varacalli, Marco Talarico et al. Nov 03, 2025 pp. 3918-3918 10.1182/blood-2025-3918

Abstract Multiple myeloma (MM) is a hematological malignancy characterized by clonal expansion of plasma cells (PC) in the bone marrow (BM),...

Changes in disease responses after discontinution of tyrosine kinase inhibitors (TKI) for pregnancy in established chronic myeloid leukaemia (CML): Evidence for the basis of advice for women of child-bearing age

Jenny Chan, Harry Robertson, Afzal Khan et al. Nov 03, 2025 pp. 3784-3784 10.1182/blood-2025-3784

Abstract The ability of women of child-bearing age to have successful pregnancies despite their diagnosis of chronic myeloid leukaemia (CML)...

Prospective registry of pediatric cellular therapy patients at risk for endothelial dysfunction, sinusoidal obstruction syndrome and/or multi-organ dysfunction syndrome(POEM):  pmods as a screening tool for endotheliopathies and critical care admission risk in pediatric HCT patients.

Shaikha Alqahtani, Hisham Abdel-Azim, Jennifer McArthur et al. Nov 03, 2025 pp. 166-166 10.1182/blood-2025-166

Abstract Background Pediatric patients undergoing hematopoietic cell transplantation (HCT) may develop life-threatening complications and ne...

Scalable, Antibody-Free Lipid Nanoparticle Achieves Human HSPC-Selective mRNA Delivery In Vivo Without Conditioning

Eunyoung Kim, Sylvanie Johnson, Ryan Zenhausern, et al. Nov 03, 2025 pp. 1067-1067 10.1182/blood-2025-1067

Abstract Cell and gene therapies for hematologic malignancies currently rely on mobilization, apheresis, ex vivo genetic manipulation, and r...

Enrichment of rare pathogenic variants in common cancer predisposition genes in lymphatic malignancy: A comprehensive analysis of 2,138 cases

Lea Dewi Schlieben, Torsten Haferlach, Wolfgang Kern et al. Nov 03, 2025 pp. 1767-1767 10.1182/blood-2025-1767

Abstract Introduction: The link between rare, inherited pathogenic variants (PVs) and an increased risk of developing specific malignancies,...

Targeting B-cell lymphoma surface protein with a novel peptide: Therapeutic potential and clinical implications

Qian Cheng, Ying Shen, Dandan Lin et al. Nov 03, 2025 pp. 2550-2550 10.1182/blood-2025-2550

Abstract Background: B-cell lymphoma has significantly improved patient survival, however, approximately 30% of patients develop relapsed/re...

Red blood cell transfusions for adolescent patients with sickle cell disease & short stature: A long term follow up study

Aamer Aleem, Abdulrahman Alsultan, Abdulrahman Altheeb et al. Nov 03, 2025 pp. 6517-6517 10.1182/blood-2025-6517

Abstract BACKGROUND: Children with sickle cell disease (SCD) commonly have delayed or impaired growth. Current evidence suggests that childr...

Trial in progress: A pivotal Phase 3 study to investigate efficacy, safety, and tolerability of mavorixafor in participants with primary chronic neutropenia – trial update

Deborah Steiner, Margo Jaffee, Katrina Adell et al. Nov 03, 2025 pp. 8229-8229 10.1182/blood-2025-8229

Abstract Background Primary chronic neutropenia (CN) is a rare immunodeficiency disorder characterized by absolute neutrophil count (ANC) &a...

Multiple ASXL1 mutations and G646fs alterations confer increased risk of leukemic Transformation in patients with myelofibrosis

Tian Zeng, Rumeng Li, Bingbing Wen et al. Nov 03, 2025 pp. 3800-3800 10.1182/blood-2025-3800

Abstract Introduction The epigenetic regulator additional sex combs-like 1 (ASXL1) is the most commonly mutated high molecular risk gene in m...

Metabolic reprogramming drives acquired venetoclax resistance in Acute Myeloid Leukemia and reveals targetable vulnerabilities

Keli Lima, Gustavo de Queiroz, Marcella Cipelli et al. Nov 03, 2025 pp. 6785-6785 10.1182/blood-2025-6785

Abstract Despite the clinical success of the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), treatment resistance frequently emer...

Switching between complement inhibitors in patients with PNH: A real-world analysis of strategy, efficacy, and safety.

Morag Griffin, Bruno Fattizzo, Jong Wook Lee et al. Nov 03, 2025 pp. 1114-1114 10.1182/blood-2025-1114

Abstract Complement inhibition (CI) for paroxysmal nocturnal hemoglobinuria (PNH) has transformed patient (pt) care. In 2025, 3 C5 inhibitor...

Predictive value of red cell distribution width for SF3B1 mutation status in myelodysplastic neoplasms

Maud Ahmad, Ian Chin-Yee, Benjamin Hedley et al. Nov 03, 2025 pp. 7401-7401 10.1182/blood-2025-7401

Abstract Background: yelodysplastic neoplasms (MDS) with SF3B1-mutations represent a distinct subtype associated with ring sideroblasts, pre...

Cerebral and peripheral microvascular function in sickle cell disease: Blood flow and oxygen extraction via diffuse correlation and Near-Infrared spectroscopy

Dheemant Jallepalli, Siddhartho Roy, Elizabeth Meinert-Spyker et al. Nov 03, 2025 pp. 2937-2937 10.1182/blood-2025-2937

Abstract Sickle cell disease (SCD) patients experience chronic anemia and vaso-occlusion leading to a lack of oxygen delivery to tissues. Th...

Real-world outcomes of FLAG-ida salvage therapy in relapsed/refractory AML and validation of the salflage score: A pethema registry study

Gaspar Aspas Requena, Rebeca Rodriguez-Veiga, Cristina Gil et al. Nov 03, 2025 pp. 1619-1619 10.1182/blood-2025-1619

Abstract Background: Most adult patients with acute myeloid leukemia (AML) will relapse after achieving a first complete remission (CR) or s...

Real-world effectiveness of pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review of clinical and patient-reported outcomes

Juan Carlos Vallejo Llamas, Koo Wilson, Zalmai Hakimi et al. Nov 03, 2025 pp. 7983-7983 10.1182/blood-2025-7983

Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare, acquired, non-malignant hematological disorder that, if left...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page